ClinicalTrials.gg
Status unknownNCT02449343Updated Apr 25, 2017

Study of Anlotinib in Patients With Soft Tissue Sarcoma(STS)(ALTER0203)

A Phase 2/3 interventional study of Anlotinib and Placebo in Soft Tissue Sarcoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 25 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-04-25.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2017), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
233
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing anlotinib in Sarcoma — 5 open to participants now, 6 under way, 1 of them phase 3. anlotinib · Sarcoma.

Enrollment
2nd of 18
233 · median 47
Started
2015
the only one that year
Phase 2/3
Only one
of the 18
Registered
1st of 18
by date
Lead sponsor
1 of 18
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 18 studies testing anlotinib in Sarcoma, this one is the 2nd largest by enrollment, is the only one that started in 2015, is the only one in phase 2/3, and was the 1st registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 365 are open to participants now.

Browse Sarcoma studies →

Open to participants now

5 of the 18 studies testing anlotinib in Sarcoma are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About anlotinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 301 Sarcoma studies recruiting now, 191 (63%) set no upper age limit and 83 (28%) stop at 75 or younger; 92 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing anlotinib in Sarcoma, or all of them as a file.
02

Study summary

Compare the effects and safety of Anlotinib with placebo in patients with soft tissue sarcoma.

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated
  • Histological documentation of Soft Tissue Sarcoma,including Synovial sarcoma、Leiomyosarcoma、Alveolar soft part sarcoma、Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma、Adipocytic Tumors、Fibrosarcoma、Clear cell sarcoma、Epithelioid sarcoma,With .
  • Within the past 6 months, using at least one failure of chemotherapy regimens (including anthracycline-based) in treating patients(except alveolar soft part sarcoma)
  • 18-70years, PS:0-1, of more than 3 months
  • Main organs function is normal
  • The woman patients of childbearing age who must agree to take methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 6 months after it

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with Anlotinib
  • With pleural effusion or ascites, cause respiratory syndrome
  • Accepted the vascular endothelial growth inhibitor class targeted drug treatment of patients
  • Plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the medicine-taking period of this research, including Cytotoxic Therapy, Signal Transduction Inhibitor, and Immunotherapy (or who use Mitomycin C within 6 weeks before taking the treatment with experimental drug); The patients who have already taken Extended Field Radiotherapy (EF-RT) within 4 weeks before grouping or Limited Field Radiotherapy with proposed assessment of nidus within 2 weeks before grouping
  • Symptoms of cannot be controlled and treated within less than 2 months
  • With severe and failed to controlled diseases
  • Occurred venous thromboembolic events within 6 months
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
233 participants (actual)

Study arms

  • Experimental
    Anlotinib

    Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

    Drug: Anlotinib

  • Placebo comparator
    Placebo

    Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

    Drug: Placebo

Interventions

  • Anlotinib p.o. qd

  • DrugPlacebo

    Placebo p.o. qd

06

What researchers measure

Primary outcomes

  1. Progress free survival (PFS)

    Time frame: up to 24 months

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: up to 24 months

  2. Objective Response Rate (ORR)

    Time frame: up to 24 months

  3. Disease Control Rate (DCR)

    Time frame: up to 24 months

07

Study locations

25 sites
  • The 1st Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Beijing Cancer Hospital
    Beijing, Beijing, China
  • Peking Union Medical College Hospital
    Beijing, Beijing, China
  • The First Affiliated Hospital of Fujian Meidical University
    Fuzhou, Fujian, China
  • Gansu Cancer Hospital
    Lanzhou, Gansu 730050, China
  • Sun Yat-Sen University Cancer Center
    Guangzhou, Guangdong 510000, China
  • The First Affiliated Hospital of Sun Yat-sen university
    Guangzhou, Guangdong, China
  • Guangxi medical university affiliated tumor hospital
    Nanning, Guangxi, China
  • The Third Hospital of hebei Medical University
    Shijiazhuang, Hebei 050051, China
  • Harbin medical university affiliated tumor hospital
    Harbin, Heilongjiang, China
  • Henan Province Tumor Hospital
    Luoyan, Henan, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Hunan Province Tumor Hospital
    Changsha, Hunan, China
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi 330029, China
  • Liaoning Province Tumor Hospital
    Shenyang, Liaoning, China
  • Ruijin Hospital Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai 200025, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
  • Fudan University Zhongshan Hospital
    Shanghai, Shanghai 200032, China
  • Shanghai General Hospital
    Shanghai, Shanghai 200080, China
  • Shanghai 6th People's Hospital
    Shanghai, Shanghai, China
  • The First Affiliated Hospital of Xian Jiaotong University
    Xian, Shanxi, China
  • West China Hospital , Sichuan University
    Chengdu, Sichuan, China
  • Tianjin Hospital
    Tianjin, Tianjin 300211, China
  • Tianjin Medical University Cancer Hospital
    Tianjin, Tianjin, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2015 (actual). Primary completion is estimated for Apr 2017, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2015
First posted
May 20, 2015
StartActual
May 12, 2015
Primary completionEst.
Apr 2017
CompletionEst.
Apr 2017
Last update
Apr 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02449343
Responsible party
Sponsor
First posted
May 20, 2015
Start date
May 12, 2015
Primary completion
Apr 2017 (estimated)
Completion
Apr 2017 (estimated)
Last update
Apr 25, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anlotinib

Start the discussion